Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available

LAVAL, Quebec, April 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management L.P. ("Pershing Square") today announced that they have released the webcast replay and accompanying presentations from the April 22, 2014 investor meeting featuring Valeant Chairman and Chief Executive Officer, J. Michael Pearson and Pershing Square Chief Executive Officer, William A. Ackman, outlining Valeant's proposed acquisition of Allergan, Inc. (NYSE: AGN).  The webcast and presentations can be accessed by visiting www.vpsevent.com/webcast.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology  and branded generics. More information about Valeant can be found at www.valeant.com.

About Pershing Square
Pershing Square Capital Management, L.P. is a SEC-registered investment advisor based in New York City.

Contact Information:

Valeant Pharmaceuticals:

Investors:

 Media:

Laurie W. Little

 Renee E. Soto/Meghan Gavigan

Valeant Pharmaceuticals International, Inc.

 Sard Verbinnen & Co.

949-461-6002

 212-687-8080

laurie.little@valeant.com 

rsoto@sardverb.com / mgavigan@sardverb.com



Pershing Square:


Carolyn Sargent


Rubenstein Associates


212-843-8030


csargent@rubenstein.com 






Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

 

 

SOURCE Valeant Pharmaceuticals International, Inc.



RELATED LINKS
http://www.valeant.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.